Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Famotidine  COVID-19 treatment studies for Famotidine  C19 studies: Famotidine  Famotidine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Death/intubation 57% Improvement Relative Risk Freedberg et al. Famotidine for COVID-19 Prophylaxis Is prophylaxis with famotidine beneficial for COVID-19? PSM retrospective 1,620 patients in the USA Lower death/intubation with famotidine (p=0.019) Freedberg et al., Gastroenterology, doi:10.1053/j.gastro.2020.05.053 Favors famotidine Favors control
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study
Freedberg et al., Gastroenterology, doi:10.1053/j.gastro.2020.05.053
Freedberg et al., Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity.., Gastroenterology, doi:10.1053/j.gastro.2020.05.053
May 2020   Source   PDF  
  All Studies   Meta
PSM retrospective 1,620 hospitalized patients in the USA, 84 with existing famotidine use, showing lower risk of combined death/intubation with treatment.
risk of death/intubation, 57.0% lower, RR 0.43, p = 0.02, treatment 8 of 84 (9.5%), control 332 of 1,536 (21.6%), NNT 8.3, propensity score matching.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Freedberg et al., 21 May 2020, retrospective, propensity score matching, USA, peer-reviewed, 15 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFamotidineAll
Abstract: Gastroenterology 2020;159:1129–1131 Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study Daniel E. Freedberg,1 Joseph Conigliaro,2,3 Timothy C. Wang,1 Kevin J. Tracey,4 Michael V. Callahan,5,6 and Julian A. Abrams,1 on behalf of the Famotidine Research Group 1 Division of Digestive and Liver Diseases, Columbia University Irving Medical Center-New York Presbyterian Hospital, New York, New York; 2Division of General Internal Medicine, Department of Medicine, Northwell Health, Manhasset, New York; 3 Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York; 4Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York; 5Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts; and 6 Office of the Assistant Secretary for Public Health Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC See Covering the Cover synopsis on page 803. Keywords: Coronavirus 2019; SARS-CoV-2; Famotidine; Histamine-2 Receptor Antagonists. C oronavirus Disease 2019 (COVID-19) caused 2 million cases and more than 150,000 deaths worldwide as of mid-April 2020.1 Clinical trials are under way to assess the efficacy of a variety of antiviral drugs; however, many of these drugs have toxicities and thus far no drug has been proven to improve outcomes in patients with COVID-19. Famotidine is a histamine-2 receptor antagonist that suppresses gastric acid production. In vitro, famotidine inhibits human immunodeficiency virus replication.2 Recently, Wu et al.3 used computational methods to predict structures of proteins encoded by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome and identified famotidine as one of the drugs most likely to inhibit the 3chymotrypsin-like protease (3CLpro), which processes proteins essential for viral replication.4 We hypothesized that famotidine would be associated with improved clinical outcomes among hospitalized patients with COVID-19. To explore this, we performed a retrospective cohort study at a single academic center located at the epicenter of the COVID-19 pandemic in the United States. Methods Complete methods are available in the Supplementary Materials. In brief, adults were eligible for the study if they were admitted to our institution from February 25, 2020, to April 13, 2020, and tested positive for SARS-CoV-2 within no more than 72 hours following admission. Patients were excluded if they died or were intubated within 48 hours following hospital admission. The primary exposure was use of famotidine (any dose, form of administration, or duration), classified as present if famotidine was received within 24 hours of hospital admission and otherwise as absent. The primary outcome was a composite of death or endotracheal intubation from hospital day 2 to day 30 (intubation-free survival). This follow-up period avoided immortal time bias because the exposure was classified based on the 24-hour period after hospitalization and the at-risk period began on hospital day 2. Cox proportional hazards modeling was performed on the full cohort, and a matched subset was examined with propensity scoring matching to balance baseline characteristics based on use of famotidine. Results Population and Use of Famotidine A total of 1620 patients met criteria for analysis, including 84 patients (5.1%) who received famotidine within 24..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop